ClinicalTrials.gg
RecruitingNCT07462377Updated Nov 17, 2026

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

A Phase 1 interventional study of EPI-326 in Epidermal Growth Factor, Epidermal Growth Factor Receptor and Epidermal Growth Factor Receptor Gene Mutation, sponsored by EpiBiologics. Recruiting at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by EpiBiologics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Nov 17, 2026First sites in South Korea and Taiwan6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 523 open to participants now, 895 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
998th of 3,000
110 · median 56
Started
2026
with 132 others
Phase 1
928 of 3,373
135 open now
Primary completion
2029-07
later than 737 of 893 live
Registered
3,285th of 3,373
by date

Among the 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 998th largest by planned enrollment of the 3,000 interventional ones that give a count, is one of 133 that started in 2026, is one of 928 in phase 1, reaches primary completion later than 737 of the 893 other live ones, and was the 3,285th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

523 of the 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

518 more — sign in →

All 523 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,373 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.

Read the detailed description

This study will be a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 as a single agent administered to patients with EGFR-mutant (per clinically validated molecular testing, e.g., next-generation sequencing [NGS]) locally advanced or metastatic NSCLC and locally advanced or metastatic HNSCC. All patients will be treated until documented disease progression, unacceptable toxicity, withdrawal of consent, or study termination.

03

Conditions studied

  • Epidermal Growth Factor
  • Epidermal Growth Factor Receptor
  • Epidermal Growth Factor Receptor Gene Mutation
  • Non Small Cell
  • Non Small Cell Lung
  • Non Small Cell Lung Cancer
  • Head and Neck
  • Head and Neck Cancer
  • Head and Neck Cancers
  • Head and Neck Squamous Cell Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma HNSCC
  • NSCLC (Non-small Cell Lung Cancer)
  • HNSCC
  • EGFR

Keywords

  • Head and Neck Squamous Cell Carcinoma
  • HNSCC
  • Epidermal Growth Factor Receptor Gene Mutation
  • EGFR
  • Non Small Cell Lung Cancer
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has a > 12 weeks at Day 1.
  2. Participant has an performance status of 0-2.
  3. Participant has confirmed NSCLC or HNSCC.

    o For NSCLC: the tumor harbors any documented EGFR mutation, insertion, or deletion.

  4. Participant has locally advanced or NSCLC or HNSCC.
  5. Participant has adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. Participant has history of uncontrolled illness.
  2. Participant has symptomatic .
  3. Participant has a diagnosis of any secondary within 3 years prior to enrollment, except for those patients treated with curative intent and no evidence of active disease.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    EPI-326

    Experimental: Dose Escalation

    Drug: EPI-326

Interventions

  • DrugEPI-326

    EPI-326 is a tissue-selective bispecific antibody for EGFR-driven cancers. EPI-326 will be administered in the clinic via IV infusion.

    Also known as: EPI-326 Injection

06

What researchers measure

Primary outcomes

  1. Evaluation of the safety and tolerability of EPI-326

    Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicity (DLTs).

    Time frame: Up to 3 years.

  2. Determination of the recommended dose and schedule for EPI-326 administration

    Maximum tolerated dose (MTD), maximum administered dose (MAD).

    Time frame: Up to 3 years.

Secondary outcomes

  1. Determination of maximum (Cmax) and minimum (Cmin) plasma concentration

    Drug concentration in the blood. To evaluate the single and multiple dose pharmacokinetic (PK) profile of EPI-326.

    Time frame: Up to 3 years.

  2. Determination of area under the concentration-time curve (AUC)

    Drug concentration in blood. To evaluate the single and multiple dose pharmacokinetic (PK) profile of EPI-326

    Time frame: Up to 3 years.

  3. Determination of clearance (CL) from the blood

    Drug concentration in blood. To evaluate the single and multiple dose pharmacokinetic (PK) profile of EPI-326

    Time frame: Up to 3 years.

  4. Determination of volume of distribution (Vd)

    Drug concentration in blood. To evaluate the single and multiple dose pharmacokinetic (PK) profile of EPI-326

    Time frame: Up to 3 years.

  5. Objective response rate (ORR)

    Time frame: Up to 3 years.

  6. Duration of response (DOR)

    Time frame: Up to 3 years.

07

Study locations

12 of 12 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jul 2029, 40 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 40 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 10, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first sites in South Korea and Taiwan
Show 6 added (4 South Korea, 2 Taiwan)
  • Samsung Medical Center · Seoul, South Korea
  • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) · Kaohsiung City, Taiwan
  • Seoul National University Bundang Hospital · Seongnam-si, South Korea
  • Seoul National University Hospital · Seoul, South Korea
  • Severance Hospital · Seoul, South Korea
  • National Taiwan University Hospital · Taipei, Taiwan
across 2 updates, Oct 14, 2026 – Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) · Kaohsiung City, TaiwanContact h•••@gmail.com→C•••@epibiologics.com · •••7486
Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    4 sites added
    Show 4 added (3 South Korea, 1 Taiwan)
    • Seoul National University Bundang Hospital · Seongnam-si, South Korea
    • Seoul National University Hospital · Seoul, South Korea
    • Severance Hospital · Seoul, South Korea
    • National Taiwan University Hospital · Taipei, Taiwan
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) · Kaohsiung City, TaiwanContact h•••@gmail.com→C•••@epibiologics.com · •••7486
    + 1 other change: verification date
  2. Oct 14, 2026
    2 sites added — first sites in South Korea and Taiwan
    Show 2 added (1 South Korea, 1 Taiwan)
    • Samsung Medical Center · Seoul, South Korea
    • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) · Kaohsiung City, Taiwan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07462377
Lead sponsor
EpiBiologics
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Mar 31, 2026
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

EpiBiologics Clinical Trials
Contact
clinicaltrials@epibiologics.com
650-955-7486

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion